Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 27, 2017
Pharmacy Choice - News - Drug Delivery Systems - May 27, 2017

Pharmacy News

 Drug Delivery Systems
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/27/17 - Dr. Reddy's Laboratories Announces the Launch of Ezetimibe and Simvastatin Tablets in the U.S. Market
HYDERABAD, India& PRINCETON, N.J. Dr. Reddy s Laboratories Ltd. announced today that it has launched Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg, a therapeutic equivalent generic version of Vytorin Tablets, in the United States market, approved by the U.S. Food and Drug Administration. The Vyto
4/27/17 - ZYDUS CADILA GETS USFDA NOD FOR ANTI-HYPERTENSIVE TABLETS
Pharmaceutical company Zydus Cadila has received final approval from the US Food and Drug Administration to market Olmesartan Medoxomil tablets in the US market. The approval is for 5 milligram, 20 milligram and 40 milligram strengths of the anti-hypertensive Olmesartan. estimated sales for Olmesartan is $982 million for twelve months to Feb 2017.
4/26/17 - "N-Acetylglucosamine Sugar Chain Group-Containing Compound, Carrier Compound for Drug Delivery, Drug Preparation, and Drug Delivery System" in Patent...
"N-Acetylglucosamine Sugar Chain Group-Containing Compound, Carrier Compound for Drug Delivery, Drug Preparation, and Drug Delivery System" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventor ISE, Hirohiko, filed on May 19, 2015, was made available online on April 13, 2
4/26/17 - Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today final 24- month results from its Phase 2 open-label extension study of patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of hATTR amyloidosis. These clinical data are being presented at the American Academy of Neurology 2017.
4/26/17 - Auto-Injectors Industry Worth USD 2.9 Billion By 2022 - Foresight Research
Auto-Injector Device Market Expected To Grow At the CAGR of~ 18%, Auto-Injector Market Size Is Expected To Increase by USD 2.9 Billion by the End of 2022| Auto-Injector Device Market. Auto injector market is expected to grow with CAGR of 17.2% from 2016 to 2022, Is Expected to Increase by USD 2.9 Billion by the End of 2022. Auto injector is defined
4/26/17 - Auto-Injectors Industry Worth USD 2.9 Billion By 2022 Foresight Research
"Auto-Injector Device Market" Auto-Injector Device Market Expected To Grow At the CAGR of~ 18%, Auto-Injector Market Size Is Expected To Increase by USD 2.9 Billion by the End of 2022| Auto-Injector Device Market Auto injector market is expected to grow with CAGR of 17.2% from 2016 to 2022, Is Expected to Increase by USD 2.9 Billion by the End of 2
4/26/17 - Braeburn Pharmaceuticals Achieves Primary Endpoint in Pivotal Phase 2/3 Study of BB0817, Risperidone 6-month Implant for Treatment of Schizophrenia
Braeburn Pharmaceuticals announced today that a 6- month study of the safety, tolerability and pharmacokinetics of transferring patients diagnosed with schizophrenia or schizoaffective disorder and stabilized on oral risperidone to BB0817 implant has met its primary endpoint. The trial was designed to demonstrate comparable average plasma...
4/26/17 - FDA Approves XATMEP?, the First and Only Ready-To-Use Methotrexate Oral Solution
Silvergate Pharmaceuticals, Inc., leaders in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved XATMEP Oral Solution, the first and only FDA- approved methotrexate oral solution. "XATMEP is an exciting product in that it provides an FDA
4/26/17 - Impax Announces FDA Approval and Launch of a Generic Version of Vytorin (Ezetimibe/Simvastatin Tablets)
Impax Laboratories, Inc., a specialty pharmaceutical company, today announced it has received final U.S. Food and Drug Administration approval for a generic version of Vytorin , 10/ 10, 10/ 20, 10/ 40 and 10/ 80 mg, and immediately initiated commercialization activities of this first-to-market opportunity. "We are pleased to be one of the firs
4/26/17 - Inspirion Delivery Sciences Receives FDA Approval for RoxyBond? (oxycodone hydrochloride) tablets CII, the First and Only Immediate Release Opioid Analgesic with Abuse-Deterrent Label Claims
Inspirion Delivery Sciences, LLC announced that the United States Food and Drug Administration has approved RoxyBond? tablets, for oral use, CII, indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. RoxyBond is an abuse-deterrent formulation of oxycodone that uses
4/26/17 - Investigators at University of Pavia Describe Findings in Drug Delivery Systems (Stem cell-extracellular vesicles as drug delivery systems: New...
According to news reporting out of Pavia, Italy, by NewsRx editors, research stated, "The aim of this work was to develop a novel carrier-in-carrier system based on stem cell-extracellular vesicles loaded of silk/curcumin nanoparticles by endogenous technique. Our news journalists obtained a quote from the research from the University of Pavia, "..
4/26/17 - Jubilant Life gets healthier after receiving USFDA nod for drug [Sudan Tribune]
Jubilant Life Sciences gained 3.82% to Rs 820.40 at 11:40 IST on BSE after the company received Abbreviated New Drug Application final approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg. The stock had hit a high of Rs 835.30 and a low of Rs 792.90 so far during the day. The stock had hit a record high of Rs 879.10 on 12 April 2017 and
4/26/17 - Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
EMERYVILLE, Calif., April 26, 2017/ PRNewswire-USNewswire/ Mercator MedSystems, Inc., a medical technology company, announced today the first patient enrollment into the TANGO clinical trial. Outside of trials using the Bullfrog device for drug delivery, only one intravascular drug delivery technology is being investigated in a single U.S. BTK st
4/26/17 - Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters
USL261 has been granted orphan drug designation and fast track designation for this use by the FDA. These findings suggest that midazolam nasal spray could be an effective rescue treatment option for patients and caregivers who live with seizure clusters, subject to FDA review, "said Bill Pullman, MB, BS, BMedSc, PhD, FRACP, President, Proximagen.
4/26/17 - New Data at AAN Reinforce Clinical Benefit of Genentech's OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis
Genentech, a member of the Roche Group, announced today that new data from the OCREVUS? clinical trial programs will be presented during the 69th American Academy of Neurology Annual Meeting in Boston, Massachusetts. The presentations will highlight new efficacy and safety analyses from the OCREVUS Phase II and Phase III trials, as well as from t
4/26/17 - New Drug Delivery Systems Data Have Been Reported by Researchers at Ministry of Education (H-II mesophase as a drug delivery system for topical...
New Drug Delivery Systems Data Have Been Reported by Researchers at Ministry of Education. According to news originating from Anhui, People's Republic of China, by NewsRx correspondents, research stated, "The main objective of this study was to develop reversed hexagonal mesophase for transdermal delivery of methyl salicylate. Our news journalists.
4/26/17 - New Drug Delivery Systems Study Findings Have Been Reported by Researchers at University of Nottingham (Engineered Polymer-Transferrin Conjugates as...
New Drug Delivery Systems Study Findings Have Been Reported by Researchers at University of Nottingham. Funders for this research include Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, The Royal Society, Albumedix Ltd. Our news editors obtained a quote from the research from the Universit
4/26/17 - New Findings on Drug Delivery Systems from Waterford Institute of Technology Summarized (Thiolated polymers as mucoadhesive drug delivery systems)
For more information on this research see: Thiolated polymers as mucoadhesive drug delivery systems. European Journal of Pharmaceutical Sciences, 2017; 100: 64-78. European Journal of Pharmaceutical Sciences can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. The news editors report that additional information may
4/26/17 - New Findings on Transdermal Delivery Discussed by Researchers at Chongqing University (Recent advances in the design of polymeric microneedles for...
New Findings on Transdermal Delivery Discussed by Researchers at Chongqing University. According to news reporting originating in Chongqing, People's Republic of China, by NewsRx journalists, research stated, "Microneedles are an efficient and minimally invasive approach to transdermal drug delivery and extraction of skin interstitial fluid.
4/26/17 - Reports on Drug Delivery Systems from School of Medicine Provide New Insights (Preparation and Ga-68-radiolabeling of porous zirconia nanoparticle...
According to news reporting from Hannover, Germany, by NewsRx journalists, research stated, "This paper describes the preparation of gallium-68 isotope labeled porous zirconia nanoparticle platform of nearly 100 nm diameter and its first pharmacokinetic and biodistribution evaluation accomplished with a microPET/CT imaging system.
4/26/17 - Researchers from Zunyi Medical University Detail New Studies and Findings in the Area of Drug Delivery Systems (Characterization, pharmacokinetics...
By a News Reporter-Staff News Editor at Biotech Week Researchers detail new data in Drugs and Therapies- Drug Delivery Systems. According to news reporting originating from Zunyi, People's Republic of China, by NewsRx correspondents, research stated, "The purpose of this study was to develop a self-microemulsifying drug delivery system to improve
4/26/17 - Study Data from L.Q.S. Lopes et al Provide New Insights into Drug Delivery Systems (Ecotoxicology of Glycerol Monolaurate nanocapsules)
By a News Reporter-Staff News Editor at Biotech Week Investigators publish new report on Drugs and Therapies- Drug Delivery Systems. According to news reporting originating in Santa Maria, Brazil, by NewsRx journalists, research stated, "Glycerol Monolaurate is a compound with known antimicrobial potential, however it is not much used due to its
4/26/17 - Tagrisso receives full approval in the EU [T-break Tech (Middle East)]
AstraZeneca today announced that the European Commission has granted full marketing authorisation for Tagrisso 40 mg and 80 mg once-daily tablets for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer. The full approval for Tagrisso is based on the.
4/26/17 - UNITED THERAPEUTICS CORP - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Factors that could cause or contribute to such differences include those described in Part II, Item 1 A-Risk Factors of this Quarterly Report on Form 10- Q; factors described in our Annual Report on Form 10- K for the year ended December 31, 2016, under the section entitled Part I, Item 1 A-Risk Factors-Forward-Looking Statements; and factors descr
4/25/17 - Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinsons Disease [Syrian Arab News Agency]
-Adamas Pharmaceuticals, Inc. today announced the presentation of two separate analyses of pooled data from the placebo-controlled Phase 3 clinical trials of ADS-5102 extended-release capsules in oral platform and poster presentation sessions at the 69th American Academy of Neurology Annual Meeting in Boston. The pooled data results, which are...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415